Antiandrogen therapy in hidradenitis suppurativa: finasteride for females
- 14 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 86-92
Abstract
Background Given its widely accepted efficacy, androgen blockade therapy for hidradenitis suppurativa (HS) has become a standard of care. Although much less frequently used than spironolactone, a small number of HS studies have reported finasteride as an alternative in women. In this study, we describe the response to and perception of finasteride therapy in a diverse cohort of women with HS. Objective We aimed to describe finasteride therapy in a diverse cohort of female patients with HS. Methods We conducted an IRB-approved retrospective chart review and telephone survey of 20 female patients, 18-years or older, with a diagnosis of HS. Finasteride was prescribed by a single provider at a specialized hidradenitis suppurativa center. Results The mean age of patients was 34.3 ± 13.5 years. Finasteride was initiated predominantly because of one or more contraindications to spironolactone or poor responsiveness. Most patients interviewed (90%; n=18) were willing to take finasteride again or continue with therapy if indicated. Ten patients (50%) reported overall satisfaction with finasteride; seven (35%) were neutral, and three (15%) were unsatisfied. No patients reported worsening disease activity while on finasteride, and only one (5%) reported decreased quality of life. When asked about side effects of finasteride, 80% (n=16) reported none; 20% (n=4) experienced one or more of the following: headache, nausea, menstrual irregularities, breast tenderness or reduced libido/sexual function. Conclusions Our study suggests that androgen blockade therapy with finasteride is a safe and effective alternative for female patients with HS who have a contraindication(s) or intolerance to spironolactone.Keywords
This publication has 21 references indexed in Scilit:
- Endocrinologic Aspects of Hidradenitis SuppurativaDermatologic Clinics, 2016
- European S1 guideline for the treatment of hidradenitis suppurativa/acne inversaJournal of the European Academy of Dermatology and Venereology, 2015
- Finasteride for the Treatment of Hidradenitis Suppurativa in Children and AdolescentsJAMA Dermatology, 2013
- Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal womenInternational Journal of Trichology, 2013
- 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair lossJournal of the European Academy of Dermatology and Venereology, 2011
- Hidradenitis suppurativa treated with finasterideJournal of Dermatological Treatment, 2005
- Finasteride as a therapy for hidradenitis suppurativaBritish Journal of Dermatology, 1999
- Mediation of hidradenitis suppurativa by androgens.BMJ, 1986
- Hidradenitis suppurativa: evidence for an endocrine abnormalityBritish Journal of Surgery, 1985
- Adverse Reactions to SpironolactoneJAMA, 1973